ACA Branded Prescription Drug Fee (Section 9008)

The ACA's branded prescription drug fee is a $2.8 billion annual industry assessment that the IRS collects from pharmaceutical manufacturers and importers whose branded drugs are sold into federal health programs. Instead of taxing each pill, Congress taxed the industry as a whole — then divided the bill in proportion to each company's share of Medicare, Medicaid, VA, and DoD sales. If your company accounts for 5% of those government program sales, your company pays 5% of $2.8 billion ($140 million). 26 CFR Part 51 sets out exactly how the IRS runs the math, notifies companies, handles disputes, and collects the money.

Current Rule (2026)

What This Rule Does

The branded prescription drug fee funds a slice of the ACA's coverage expansion by drawing on the industry that stands to benefit from expanded insurance coverage — more insured patients means more drug sales. Congress designed the fee as an aggregate assessment rather than a per-unit tax for a specific reason: it doesn't distort pricing at the individual drug level. A $5 generic and a $5,000 branded specialty drug both contribute based on actual government program sales, not a per-pill rate. For context on the broader ACA financing architecture, see the ACA Health Insurance Marketplace and ACA Employer Mandate.

Who pays: Any manufacturer or importer of branded drugs — drugs approved under an NDA or BLA from the FDA — with more than $5 million in annual government program sales. Generic drugs (sold under ANDAs), veterinary-only drugs, vaccines, and certain orphan drugs are excluded. In practice, the fee falls almost entirely on large brand-name pharmaceutical companies: the top 10 pharma companies by Medicare Part D spend collectively generate the vast majority of the taxable sales base.

How payment works: The IRS doesn't wait for companies to self-report what they owe. Instead, it pulls government program sales data directly from CMS (Medicare and Medicaid), the Department of Defense (TRICARE), and the VA, calculates each company's share, and sends a preliminary fee notice. Companies then have 30 days to dispute errors — wrong NDC codes, misattributed drugs, data discrepancies — before the IRS issues a final notice with a payment deadline (historically September). Payments must be made electronically and are treated as excise tax collections if unpaid.

The most counterintuitive feature: the fee is non-deductible. Most business costs reduce taxable income; this one doesn't. Under 26 U.S.C. § 275(a)(6), companies can't write off the fee, which means its effective pre-tax cost is higher than the nominal amount. At a 21% corporate tax rate, a $100 million fee costs approximately $127 million in pre-tax equivalent dollars.

Key Mechanics

The allocation formula (§ 51.5) is straightforward arithmetic: take your company's branded drug sales to covered government programs, divide by total industry sales to those same programs, and multiply by $2.8 billion. That ratio is your fee. The formula is mechanical — there's no negotiation over the aggregate amount; Congress fixed that in statute.

Covered entity definition (§ 51.2): The fee follows the brand holder, not the contract manufacturer. If Company A holds the NDA for a drug and contracts Company B to produce it, Company A owes the fee. The $5 million sales threshold exists to keep the IRS from chasing very small companies through the administrative process; most small-volume branded manufacturers fall below it.

Form 8947 — the operational lever (§ 51.4): Covered entities must file Form 8947 listing their National Drug Code (NDC) identifiers for all branded drugs. The NDC is how government programs track drug purchases, and it's how the IRS matches company identity to sales records. Miss the filing deadline or omit NDC codes, and the IRS calculates your fee on incomplete data — potentially over-assessing you for drugs it can't properly attribute to your competitors. Getting Form 8947 right is a compliance priority, not a formality.

Orphan drug exclusion (§ 51.6): Sales of drugs that carry FDA orphan drug designation — approved solely for rare diseases — are excluded from the sales base. The logic is that government programs are often the dominant payer for orphan diseases, so including those sales would create a perverse penalty for rare-disease drug development. See Orphan Drug Act for how orphan designation is granted and maintained. But the exclusion has limits: once a drug receives an approval for a non-orphan indication, the exclusion disappears for sales attributable to that use. Manufacturers of drugs that straddle orphan and non-orphan indications must track which sales qualify for exclusion.

Controlled group rules (§ 51.9): Subsidiaries and parent corporations under common control are treated as a single entity for fee calculation purposes. Sales are pooled at the group level, the group's fee is calculated, and then allocated internally. This prevents corporate restructuring games where a company breaks into subsidiaries each under the $5 million threshold.

Dispute window (§ 51.7): The 30-day dispute period after the preliminary notice is the only formal opportunity to correct IRS data errors. Supporting documentation — CMS data extracts, NDC verification, entity attribution records — must be submitted in that window. Disputes raised after the final notice face a much higher bar.

How It Affects You

If you work in pharmaceutical government affairs, pricing, or regulatory: The branded drug fee is a fixed annual overhead cost driven entirely by your government program sales mix. Because it's non-deductible, model it at effective cost: nominal fee ÷ (1 − tax rate). At 21% corporate rate, a $50 million assessment carries a $63 million pre-tax equivalent burden. Companies with high Medicare Part D concentration — specialty pharmaceuticals, oncology, biologics — pay a disproportionate share because government programs dominate their revenue mix. The NDC filing on Form 8947 is not a set-it-and-forget-it exercise: acquisitions, new FDA approvals, and drug discontinuations all require updating your NDC roster to avoid over- or under-assessment.

If you're a policy analyst or healthcare economist: The fee is an interesting policy instrument precisely because it doesn't operate like a normal tax. It doesn't change the per-unit price of any specific drug; it's a fixed annual levy distributed by market share. Economic literature suggests a meaningful portion of the fee is passed through to private payers through higher list prices or lower rebates over time — which means the "industry" fee may partly become a consumer and commercial-insurance cost. CBO estimated the fee would raise approximately $35 billion over 10 years when the ACA was enacted; actual collections through 2025 track roughly to that projection. The Tax Cuts and Jobs Act (2017) left the fee structure intact despite significant restructuring of other business taxes. Compare this fee structure to the parallel ACA financing mechanism — the ACA health insurer fee and PCORI excise tax — which place similar industry-wide assessments on health insurers and employer plans.

If you're a startup or early-stage biopharmaceutical company: The $5 million threshold is a real safe harbor. Pre-commercial companies and companies with modest government program penetration owe nothing. Your fee obligation grows as Medicare and Medicaid sales grow — which means the fee effectively scales with your commercial success in government programs. If you're developing orphan drugs, track your FDA designation status carefully: approval of a second, non-orphan indication can eliminate the exclusion on a significant portion of your sales, triggering fee obligations you didn't model.

If you're an employer or benefits manager: The fee is an upstream cost borne by pharmaceutical manufacturers, not a direct charge to employers or employees. But economic incidence matters: if manufacturers pass the fee through to commercial payers via higher list prices or reduced rebates, your pharmacy benefit costs may be higher than they would be without the fee. It's one of several ACA financing mechanisms that affect commercial health insurance costs indirectly.

Legal Authority

The fee rests on two statutory provisions:

• 26 U.S.C. § 9008 — Core authority for the branded prescription drug fee: defines "covered entity," specifies covered government programs (Medicare Parts B and D, Medicaid, DoD/TRICARE, VA), sets the aggregate fee schedule by year, grants IRS administrative authority, and designates the fee as non-deductible.
• 26 U.S.C. § 275(a)(6) — Prohibits deduction of the branded prescription drug fee as a business expense, increasing the effective cost relative to an ordinary deductible business cost.

The implementing regulation — 26 CFR Part 51 — was finalized at 76 FR 38051 (June 29, 2011) and has not been substantively amended since. Annual procedural updates (Form 8947 instructions, notice calendars) are issued as IRS notices, not Federal Register rulemakings.

Recent Developments

The fee structure has been stable since 2019, when the aggregate amount settled permanently at $2.8 billion following a phased-in schedule:

The 2017–2018 spike was a statutory step-up Congress built into the original ACA text. The Inflation Reduction Act of 2022 — which restructured Medicare drug pricing through direct negotiation under 42 U.S.C. § 1320f — did not modify the Section 9008 fee. As Medicare begins direct price negotiations under the IRA, the sales base for covered entities may shift: lower negotiated prices would reduce absolute dollar sales to Medicare Part D, which could slightly reduce some manufacturers' fee allocations while increasing others'.

Republican budget proposals in 2025 floated repealing or restructuring several ACA financing mechanisms; the branded drug fee was identified in some proposals as a candidate for elimination or reduction as part of broader pharmaceutical industry negotiations. No legislative action on the fee had been enacted as of early 2026.

Pending Legislation

• HR 114 (Rep. Biggs, R-AZ) — Responsible Path to Full Obamacare Repeal Act (119th Congress): Full repeal of the ACA, effective October 1, 2025. Would eliminate Section 9008 and the branded prescription drug fee entirely by restoring the pre-ACA statutory framework. Status: Introduced, January 2025. No committee action.
• S 2749 (Sen. Whitehouse, D-RI) — Exempts Medicare from sequestration reductions caused by the One Big Beautiful Bill Act. Relevant because OBBA-driven Medicare sequestration could affect Part D sales levels that underpin drug fee allocations. Status: Introduced, September 2025.
• HR 1492 (Rep. Murphy, R-NC) — Amends the Drug Price Negotiation Program under the IRA to equalize negotiation timelines between small-molecule drugs and biologics (7 → 11 years for small molecules). If enacted, would delay negotiated price reductions for small-molecule drugs, preserving higher Medicare Part D sales values that flow into branded drug fee calculations. Status: Introduced, February 2025.

Pending Action

No active rulemaking is pending for 26 CFR Part 51. The IRS updates Form 8947 instructions annually but has not proposed structural changes to the fee calculation, dispute process, or covered entity definitions. Monitor IRS guidance releases and any budget reconciliation legislation for potential changes to the aggregate fee amount or coverage scope, particularly in the context of IRA drug pricing reforms that alter the Medicare sales base.

One Big Beautiful Bill Act (P.L. 119-XX, signed July 4, 2025): The reconciliation law enacted in July 2025 made significant Medicaid and Medicare changes but did not directly modify the branded prescription drug fee under 26 U.S.C. § 9008. However, OBBA's Medicaid restructuring — including work requirements for able-bodied adults and per-capita cap proposals — could reduce Medicaid drug expenditures over time, shrinking the Medicaid component of the fee calculation base for manufacturers with high Medicaid concentration.